Phase I trial of ruxolitinib plus fostamatinib for the treatment of steroid refractory chronic graft versus host disease
Publication
, Conference
Lin, C; Li, Z; Owzar, K; Sibley, A; Jia, W; Spasojevic, I; Chao, N; Lopez, R; Long, G; Hong, S; Bush, A; Tichon, J; Hill, L; Horwitz, M ...
Published in: Blood
November 3, 2025
Duke Scholars
Published In
Blood
DOI
EISSN
1528-0020
ISSN
0006-4971
Publication Date
November 3, 2025
Volume
146
Issue
Supplement 1
Start / End Page
2479 / 2479
Publisher
American Society of Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Lin, C., Li, Z., Owzar, K., Sibley, A., Jia, W., Spasojevic, I., … Sarantopoulos, S. (2025). Phase I trial of ruxolitinib plus fostamatinib for the treatment of steroid refractory chronic graft versus host disease. In Blood (Vol. 146, pp. 2479–2479). American Society of Hematology. https://doi.org/10.1182/blood-2025-2479
Lin, Chenyu, Zhiguo Li, Kouros Owzar, Alexander Sibley, Wei Jia, Ivan Spasojevic, Nelson Chao, et al. “Phase I trial of ruxolitinib plus fostamatinib for the treatment of steroid refractory chronic graft versus host disease.” In Blood, 146:2479–2479. American Society of Hematology, 2025. https://doi.org/10.1182/blood-2025-2479.
Lin C, Li Z, Owzar K, Sibley A, Jia W, Spasojevic I, et al. Phase I trial of ruxolitinib plus fostamatinib for the treatment of steroid refractory chronic graft versus host disease. In: Blood. American Society of Hematology; 2025. p. 2479–2479.
Lin, Chenyu, et al. “Phase I trial of ruxolitinib plus fostamatinib for the treatment of steroid refractory chronic graft versus host disease.” Blood, vol. 146, no. Supplement 1, American Society of Hematology, 2025, pp. 2479–2479. Crossref, doi:10.1182/blood-2025-2479.
Lin C, Li Z, Owzar K, Sibley A, Jia W, Spasojevic I, Chao N, Lopez R, Long G, Hong S, Bush A, Tichon J, Hill L, Horwitz M, Sarantopoulos S. Phase I trial of ruxolitinib plus fostamatinib for the treatment of steroid refractory chronic graft versus host disease. Blood. American Society of Hematology; 2025. p. 2479–2479.
Published In
Blood
DOI
EISSN
1528-0020
ISSN
0006-4971
Publication Date
November 3, 2025
Volume
146
Issue
Supplement 1
Start / End Page
2479 / 2479
Publisher
American Society of Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology